Literature DB >> 28586179

Improved posttransplant mortality after share 35 for liver transplantation.

Allison J Kwong1, Aparna Goel1, Ajitha Mannalithara1, W Ray Kim1.   

Abstract

The Share 35 policy was implemented in June 2013 to improve equity in access to liver transplantation (LT) between patients with fulminant liver failure and those with cirrhosis and severe hepatic decompensation. The aim of this study was to assess post-LT outcomes after Share 35. Relevant donor, procurement, and recipient data were extracted from the Organ Procurement and Transplantation Network/United Network for Organ Sharing database. All adult deceased donor LTs from January 1, 2010, to March 31, 2016, were included in the analysis. One-year patient survival before and after Share 35 was assessed by multivariable Cox proportional hazards analysis, with adjustment for variables known to affect graft survival. Of 34,975 adult LT recipients, 16,472 (47.1%) were transplanted after the implementation of Share 35, of whom 4,599 (27.9%) had a Model for End-Stage Liver Disease (MELD) score ≥35. One-year patient survival improved from 83.9% to 88.4% after Share 35 (P < 0.01) for patients with MELD ≥35. There was no significant impact on survival of patients with MELD <35 (P = 0.69). Quality of donor organs, as measured by a donor risk index without the regional share component, improved for patients with MELD ≥35 (P < 0.01) and worsened for patients with lower MELD (P < 0.01). In multivariable Cox regression analysis, Share 35 was associated with improved 1-year patient survival (hazard ratio, 0.69; 95% confidence interval, 0.60-0.80) in recipients with MELD ≥35.
CONCLUSION: Share 35 has had a positive impact on survival after transplantation in patients with MELD ≥35, without a reciprocal detriment in patients with lower acuity; this was in part a result of more favorable donor-recipient matching. (Hepatology 2018;67:273-281).
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2017        PMID: 28586179      PMCID: PMC5756050          DOI: 10.1002/hep.29301

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  26 in total

1.  Simulating the allocation of organs for transplantation.

Authors:  David Thompson; Larry Waisanen; Robert Wolfe; Robert M Merion; Keith McCullough; Ann Rodgers
Journal:  Health Care Manag Sci       Date:  2004-11

2.  First Look: One Year Since Inception of Regional Share 35 Policy.

Authors:  A Annamalai; W Ayoub; V Sundaram; A Klein
Journal:  Transplant Proc       Date:  2015 Jul-Aug       Impact factor: 1.066

3.  Early changes in liver distribution following implementation of Share 35.

Authors:  A B Massie; E K H Chow; C E Wickliffe; X Luo; S E Gentry; D C Mulligan; D L Segev
Journal:  Am J Transplant       Date:  2015-03       Impact factor: 8.086

4.  Outcome of liver transplantation based on donor graft quality and recipient status.

Authors:  B Nemes; F Gelley; G Zádori; L Piros; J Perneczky; L Kóbori; I Fehérvári; D Görög
Journal:  Transplant Proc       Date:  2010 Jul-Aug       Impact factor: 1.066

Review 5.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

6.  End-stage liver disease candidates at the highest model for end-stage liver disease scores have higher wait-list mortality than status-1A candidates.

Authors:  Pratima Sharma; Douglas E Schaubel; Qi Gong; Mary Guidinger; Robert M Merion
Journal:  Hepatology       Date:  2011-11-15       Impact factor: 17.425

7.  Waitlist Outcomes of Liver Transplant Candidates Who Were Reprioritized Under Share 35.

Authors:  E K H Chow; A B Massie; X Luo; C E Wickliffe; S E Gentry; A M Cameron; D L Segev
Journal:  Am J Transplant       Date:  2016-08-24       Impact factor: 8.086

8.  Liver transplantation after share 35: Impact on pretransplant and posttransplant costs and mortality.

Authors:  Clara T Nicolas; Scott L Nyberg; Julie K Heimbach; Kymberly Watt; Harvey S Chen; Matthew A Hathcock; Walter K Kremers
Journal:  Liver Transpl       Date:  2016-12-05       Impact factor: 5.799

9.  Regional sharing for adult status 1 candidates: reduction in waitlist mortality.

Authors:  Kenneth Washburn; Ann Harper; Goran Klintmalm; John Goss; Glenn Halff
Journal:  Liver Transpl       Date:  2006-03       Impact factor: 5.799

10.  Effects of Donor Age and Cold Ischemia on Liver Transplantation Outcomes According to the Severity of Recipient Status.

Authors:  Michał Grąt; Karolina M Wronka; Waldemar Patkowski; Jan Stypułkowski; Karolina Grąt; Maciej Krasnodębski; Łukasz Masior; Zbigniew Lewandowski; Marek Krawczyk
Journal:  Dig Dis Sci       Date:  2016-02       Impact factor: 3.199

View more
  13 in total

1.  Women who undergo liver transplant have longer length of stay post-transplant compared with men.

Authors:  Jessica B Rubin; Giuseppe Cullaro; Jin Ge; Jennifer C Lai
Journal:  Liver Int       Date:  2020-05-25       Impact factor: 5.828

2.  Lower Likelihood of Post-transplant Graft Failure, Death, and Retransplantation in the Era of Direct-Acting Antivirals.

Authors:  Kellie Young; Benny Liu; Taft Bhuket; Robert J Wong
Journal:  J Clin Exp Hepatol       Date:  2020-02-21

3.  Trends of characteristics and outcomes of donors and recipients of deceased donor liver transplantation in the United States: 1990 to 2013.

Authors:  Subhashini Ayloo; Sri Ram Pentakota; Michele Molinari
Journal:  World J Transplant       Date:  2018-09-10

Review 4.  Approaches for patients with very high MELD scores.

Authors:  Florent Artru; Didier Samuel
Journal:  JHEP Rep       Date:  2019-02-23

5.  The von Willebrand Factor Facilitates Model for End-Stage Liver Disease-Independent Risk Stratification on the Waiting List for Liver Transplantation.

Authors:  Georg P Györi; David Pereyra; Benedikt Rumpf; Hubert Hackl; Christoph Köditz; Gregor Ortmayr; Thomas Reiberger; Michael Trauner; Gabriela A Berlakovich; Patrick Starlinger
Journal:  Hepatology       Date:  2020-04-23       Impact factor: 17.425

6.  The Addition of C-Reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease-Sodium Improves Prediction of Waitlist Mortality.

Authors:  Patrick Starlinger; Joseph C Ahn; Aidan Mullan; Georg P Gyoeri; David Pereyra; Roberto Alva-Ruiz; Hubert Hackl; Thomas Reiberger; Michael Trauner; Jonas Santol; Benedikt Simbrunner; Mattias Mandorfer; Gabriela Berlakovich; Patrick S Kamath; Julie Heimbach
Journal:  Hepatology       Date:  2021-08-29       Impact factor: 17.425

7.  The Role of von Willebrand Factor Antigen in Predicting Survival of Patients with HBV-Related Cirrhosis.

Authors:  Youmin Pan; Renyong Guo; Yan Lv; Dawei Cui; Jue Xie
Journal:  Can J Gastroenterol Hepatol       Date:  2022-03-22

8.  Live Donor Liver Transplantation in the United States: Impact of Share 35 on Live Donor Utilization.

Authors:  Hillary J Braun; Jennifer L Dodge; Joshua D Grab; Marisa E Schwab; Iris H Liu; Alexa C Glencer; Peter G Stock; Ryutaro Hirose; John P Roberts; Nancy L Ascher
Journal:  Transplantation       Date:  2021-04-01       Impact factor: 5.385

9.  Use of rapid Model for End-Stage Liver Disease (MELD) increases for liver transplant registrant prioritization after MELD-Na and Share 35, an evaluation using data from the United Network for Organ Sharing.

Authors:  Guy N Brock; Kenneth Washburn; Michael R Marvin
Journal:  PLoS One       Date:  2019-10-03       Impact factor: 3.240

10.  Mitochondrial Consequences of Organ Preservation Techniques during Liver Transplantation.

Authors:  Tamara Horváth; Dávid Kurszán Jász; Bálint Baráth; Marietta Zita Poles; Mihály Boros; Petra Hartmann
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.